Glenmark receives ANDA approval for Calcipotriene Cream

Calcipotriene Cream is for the treatment of psoriasis


The drug is the therapeutic equivalent of Dovonex Cream

Glenmark Pharmaceuticals has been granted final approval by the United States Food and Drug Administration (US FDA) for Calcipotriene Cream, 0.005 percent. The drug is the therapeutic equivalent of Dovonex Cream, 0.005 percent of Leo Pharma A/S.

The company plans to commence shipping of Calcipotriene Cream, 0.005 percent immediately.

According to IMS Health sales data for the 12 month period ending April 2015, the Dovonex market achieved annual sales of approximately $91.9 million.



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email